PubMed

Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.

Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, Meinus S, Reinecke F, Möhlig M, Weickert MO, Clemenz M, Pfeiffer AF, Kintscher U, Spuler S, Spranger J.

Diabetes. 2009 Jul;58(7):1532-8. Epub 2009 Apr 28.PMID: 19401423 [PubMed - indexed for MEDLINE]Related articlesFree article

The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.

Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J.

J Am Coll Cardiol. 2008 Sep 2;52(10):869-81. Epub 2008 Jul 2.PMID: 18755353 [PubMed - indexed for MEDLINE]Related articlesFree article

Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.

Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P.

Int J Obes (Lond). 2007 Aug;31(8):1302-10. Epub 2007 Feb 20.PMID: 17310221 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

Frias JP, Yu JG, Kruszynska YT, Olefsky JM.

Diabetes Care. 2000 Jan;23(1):64-9.PMID: 10857970 [PubMed - indexed for MEDLINE]Related articlesFree article

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. Epub 2008 Feb 14.PMID: 18346728 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.

Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S.

Ann Intern Med. 2004 May 18;140(10):786-94.PMID: 15148065 [PubMed - indexed for MEDLINE]Related articlesFree article

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.

Mol Endocrinol. 2005 Jun;19(6):1593-605. Epub 2005 Apr 14.PMID: 15831517 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.

Li K, Li L, Yang M, Zong H, Liu H, Yang G.

Eur J Endocrinol. 2009 Sep;161(3):391-5. Epub 2009 Jun 15.PMID: 19528204 [PubMed - indexed for MEDLINE]Related articles

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.

Serlie MJ, Allick G, Groener JE, Ackermans MT, Heijligenberg R, Voermans BC, Aerts JM, Meijer AJ, Sauerwein HP.

J Clin Endocrinol Metab. 2007 Jan;92(1):166-71. Epub 2006 Oct 24.PMID: 17062758 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.

Wake DJ, Stimson RH, Tan GD, Homer NZ, Andrew R, Karpe F, Walker BR.

J Clin Endocrinol Metab. 2007 May;92(5):1848-56. Epub 2007 Feb 27.PMID: 17327378 [PubMed - indexed for MEDLINE]Related articlesFree article

Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.

Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW.

Endocrinology. 2006 Sep;147(9):4252-62. Epub 2006 May 25.PMID: 16728496 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.

Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.

Diabetes. 2000 Apr;49(4):633-9.PMID: 10871202 [PubMed - indexed for MEDLINE]Related articlesFree article

Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone.

Hällsten K, Virtanen KA, Lönnqvist F, Janatuinen T, Turiceanu M, Rönnemaa T, Viikari J, Lehtimäki T, Knuuti J, Nuutila P.

Diabet Med. 2004 Dec;21(12):1280-7.PMID: 15569129 [PubMed - indexed for MEDLINE]Related articles

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.PMID: 17520238 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.

Oakes ND, Thalén PG, Jacinto SM, Ljung B.

Diabetes. 2001 May;50(5):1158-65.PMID: 11334421 [PubMed - indexed for MEDLINE]Related articlesFree article

The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes.

Mazzucotelli A, Viguerie N, Tiraby C, Annicotte JS, Mairal A, Klimcakova E, Lepin E, Delmar P, Dejean S, Tavernier G, Lefort C, Hidalgo J, Pineau T, Fajas L, Clément K, Langin D.

Diabetes. 2007 Oct;56(10):2467-75. Epub 2007 Jul 23.PMID: 17646210 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.

J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. Epub 2007 Oct 23.PMID: 17956948 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA.

Kidney Int. 2007 Dec;72(11):1367-73. Epub 2007 Sep 5.PMID: 17805239 [PubMed - indexed for MEDLINE]Related articles

Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans.

Staiger H, Haas C, Machann J, Werner R, Weisser M, Schick F, Machicao F, Stefan N, Fritsche A, Häring HU.

Diabetes. 2009 Mar;58(3):579-89. Epub 2008 Dec 15.PMID: 19074989 [PubMed - indexed for MEDLINE]Related articlesFree article